news aktuell GmbH

nal von minden: Did my vaccine work? New rapid test for the determination of vaccination success.

25.5.2021 11:46:53 CEST | news aktuell GmbH | Press release

Share
Am I really protected against the coronavirus now? This is a question asked by many after receiving a vaccination. The medtech company nal von minden from Moers in Germany has now developed a rapid test that can reliably detect antibodies against COVID-19 pathogens in blood. The NADAL® COVID-19 S1-NAb Test is now available all over Europe.

(Moers, Germany): “People want clarity once they been vaccinated against coronavirus: They want to know if it has worked“ says Thomas Zander, CEO of nal von minden GmbH. Depending on the particular vaccine used, the COVID-19 vaccines offer 70% or more protection from the disease – but not 100%.


If the vaccine has ‘worked’, the body produces human antibodies against the disease. “These antibodies ensure that, in the event of exposure, the disease pathogens – the coronaviruses – would be readily identified and quickly repelled. Rather like the police on alert.”

These antibodies can be found in human blood and, if present, are easily detectable. With the NADAL® COVID-19 S1-NAb Test, the process takes just a few minutes. Thomas Zander explains: “Our new rapid test for the detection of coronavirus antibodies can be carried out by your GP in the future, as the test is currently only for professional use. A tiny prick of the finger is enough. The little drop of blood is added to the accompanying test cassette, and results can be read within 15 minutes.”

The new rapid test has already been comprehensively studied in the USA and China. “In the USA and China the vaccination programmes are more progressed, so the first studies were carried out there,” says Zander. “Further quality studies at German research centres will follow shortly.” It has been confirmed that the antibody test works for all kinds of vaccines (BioNtech, AstraZeneca, Johnson&Johnson, Sinovac and Moderna).

Coronavirus vaccinations usually take place across two appointments, and the new rapid test can be carried out either two weeks after the first vaccination, or two weeks after the second, says Thomas Zander. “Those who produce an immune response following the first vaccine – which can cause, for example, mild cold-like symptoms – can first wait until after the second vaccination.” Of course, the test can also be carried out weeks or even months afterwards, as nobody yet knows how long the vaccinations protect us against coronaviruses.

Contacts

Gabriele Hellwig, info@hellwig-pr.de

Images

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Advanced Robotics Conference 2026: FEV highlights pathways to industrial deployment of Physical AI19.11.2026 11:00:00 CET | Press release

Aachen, Germany, November 2026 – The Advanced Robotics Conference (ARC) 2026 will bring together leading representatives from international technology companies, start-ups, and research institutions at FEV’s headquarters in Aachen, Germany, on November 25 and 26. The event will focus on the latest technological developments, specific fields of application, and the prerequisites for the widespread adoption of advanced robotics.

Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored17.11.2026 16:00:00 CET | Press release

Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp honored for groundbreaking research on metabolic diseases and obesity therapies. Minister-President Boris Rhein presents the medical award, endowed with a total of one million euros, at the Hessian State Chancellery. Titia große Broermann: " this year’s laureates powerfully demonstrate how scientific curiosity sparks medical progress that can transform millions of lives”

Infomaniak and Gruyère Energie develop a data center project in Bulle designed to limit its footprint13.11.2026 13:41:04 CET | Press release

Geneva and Bulle, 13 November 2026 – Infomaniak SA (SIX: INFO), a Swiss cloud provider, and Gruyère Energie SA announce that the planning application for a data center in Bulle will be put on public display on 13 November. Planned for 2028, this next-generation facility is intended to meet growing digital needs while reusing the heat produced by its servers in the existing district heating network. Its planned IT capacity of 2.5 megawatts (MW) is twice that of Infomaniak’s most recent data center, in Geneva. The project remains modest in size.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye